Bendamustine/Rituximab and Maintenance Lenalidomide in Relapsed/Refractory CLL and SLL


Bendamustine/Rituximab and Maintenance Lenalidomide in Relapsed/Refractory CLL and SLL
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Bruce D Cheson, MD (1/14/13)
Chang JE et al. Bendamustine + rituximab (BR) chemoimmunotherapy and maintenance lenalidomide in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): A Wisconsin Oncology Network (WON) study. Proc ASH 2012;Abstract 3647.

Dr Cheson is Professor of Medicine, Deputy Chief of the Division of Hematology-Oncology and Head of Hematology at the Georgetown University Hospital Lombardi Comprehensive Cancer Center in Washington, DC.